CDx: more partnerships ahead, but more pharma awareness needed
This article was originally published in Scrip
Executive Summary
Arguably the most significant catalyst for the greater adoption of personalised medicine came in July 2011 when the US FDA issued its draft guidance on companion diagnostics (scripintelligence.com, 18 July 2011). It didn’t do the whole job, in that it still leaves questions open about how to design and conduct clinical trials. But it did provide a clear signal that the pharma industry should continue moving towards adopting a bigger role for diagnostics as its business model evolves.